Evaluating the Role of 340B in Managing Healthcare Costs for Taft-Hartley Plans
Download Taft Hartley Plans PDF Download the one pager In the United States, unlike other countries, the net prices of medications are generally treated as trade secrets; with information regarding a drug’s net price amount not readily available in the public domain. Since the passage of the anti-kickback statute and the establishment of the various […]
Most-Favored-Nation Drug Pricing: A Threat to American Workers and Innovation
Most-Favored-Nation (MFN) foreign reference pricing is the wrong approach to lowering drug costs. It will hurt patients, endanger good-paying union jobs, and hand the strategic advantage to China—precisely when manufacturing reshoring momentum is building across the country. Devastating Consequences for American Workers The U.S. biopharmaceutical industry supports nearly 5 million jobs nationwide and contributes moreto […]
An Understanding and Implications of the Cost Drivers in the Drug Supply Chain
The Pharmaceutical Industry Labor Management Association (or PILMA) is proud to offer this assessment of the current drivers inherent in the drug supply chain which contribute to the overall costs of getting our country’s prescription drugs to the consumer.
Impact of Medicare Part D Rebates on Multi-employer Plans
Medicare Part D is a successful program that has brought prescription drug coverage to millions of seniors, while keeping costs lower than expected with high levels of beneficiary satisfaction.
Jobs Today: Cures Tomorrow—Innovation and the Biopharmaceutical Industry
Our nation’s biopharmaceutical industry is vital to the personal health of our people and the economic health of our country. At the current time, and in the current political and regulatory environment, we are at the edge of a precipice
Health Care Reform for Workers and Working Families
Each day, hundreds of thousands of workers in the United States start their day researching, developing and manufacturing biopharmaceutical products, and building the facilities where those medicines are discovered or produced.